Video

Overcoming Racial Inequality in Epithelial Ovarian Cancer Research

Danja Sarink, PhD, discusses the importance of studying race and ethnicity in epithelial ovarian cancer research.

Danja Sarink, PhD, postdoctoral research fellow, ​Department of Cancer Epidemiology, University of Hawai’​i Cancer Center, discusses the importance of studying race and ethnicity in epithelial ovarian cancer research.

​Epithelial ovarian cancer is a rare disease and most cohort studies only have a small proportion of non-White women, making it hard to evaluate risk factors for these women in prospective studies, says Sarink.

​However, a recent study led by Sarink evaluated the incidence of epithelial ovarian cancer across different ethnic groups ​including Native Hawaiians, Japanese Americans, and Latinas.

The study found that Native Hawaiian women had an increased risk of epithelial ovarian cancer compared with Caucasian women, while Japanese Americans and Latinas had a decreased risk. Differences in risk factors, such as parity or exogenous hormone use, between racial/ethnic groups did not explain these differences in epithelial ovarian cancer risk.

As such, there ​remains a need to conduct further research in this space, Sarink concludes.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic